XOMA gets scooped up, and the stock pops

Deal candy, not a growth story

XOMA Royalty just got the kind of Monday pop that makes traders stop doomscrolling and check the tape twice. Ligand Pharmaceuticals said it plans to buy the royalty company for $39 per share in cash, which is why XOMA ripped higher while the broader market was taking a nap.

Why your investor brain should care

This isn’t about quarterly vibes or some spicy new product launch. It’s a straight-up cash acquisition, which usually turns the stock into a simple arithmetic puzzle: will the deal close, and how long do you have to wait for the money?

A few moving pieces here:

• XOMA Royalty is now trading like a deal stock, not an independent story
• Ligand is the buyer, so its capital allocation gets a little more interesting too
• The spread between the current price and the offer price becomes the market’s favorite little obsession

Meanwhile, the rest of the market was being extra

The article also name-checked a bunch of other stocks popping around the tape, from Oruka Therapeutics after interim psoriasis trial data to Repay Holdings after it lifted its revenue outlook. But the headline mover was XOMA, and the message is simple: when a company gets taken out for cash, the old thesis gets replaced by merger math.

Big picture: for XOMA shareholders, this is less “build the future” and more “count the chips.” The only real question now is whether the deal closes cleanly or turns into one of those painfully slow corporate weddings with too many speeches.